ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG), also known as osteoclast inhibitory factor, is a soluble receptor of the tumor necrosis factor receptor superfamily. The protein is secreted as a covalent, disulfide-linked homodimer, which is the predominant extracellular form (1), and is expressed in multiple tissues (1)(2)(3). OPG-mediated pathways might have a role in osteoporosis (3)(4)(5)(6) because estrogen increases OPG gene expression (4)(5). OPG maintains the structure of healthy bone and inhibits osteoclast activation and differentiation (3)(7). In the vascular system, OPG inhibits pathological calcification in the media intima (3). OPG has been proposed for therapy of osteopenic disorders, such as postmenopausal osteoporosis, Paget disease, rheumatoid arthritis, hypercalcemia, and lytic bone metastases (8). Initially, we developed an antibody-based ELISA method with an anti-human OPG monoclonal antibody for capture and an anti-human OPG polyclonal antibody for detection. Yano et al. (9) raised the concern for us that we may not detect the active dimeric OPG with antibody capture because they reported that serum OPG increased with age and that the monomer was the predominant form of OPG in human serum. Although they used a different antibody-dependent ELISA method (monoclonal capture and detection), the results reported by Yano et al. (9) do not correspond with the work performed at Amgen (1)(3)(4)(5)(7)(8)(10)(11)(12). We reasoned that OPG ligand (OPGL) (2)(7)(8)(10)(11)(12)(13)(14)(15)(16), also known as osteoclast differentiation factor, is a potential alternative capture protein for an OPG assay. In an attempt to develop an assay that would measure all bioactive form(s) of OPG, we developed an ELISA assay that uses OPGL as the capture protein. To avoid problems posed by batch-to-batch variability of human serum pools for use as assay diluent, assay development was used to define a serum substitute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.
Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S.-I., Yasuda, H., Morinaga, T., Tsuda, E., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8443 · Cited by 83
Cited by
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“One research group has used RANKL-coated microtiter plates to capture OPG in serum, along with a monoclonal detection antibody (38, 39).”
BackgroundMethodCorrelates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205
“Since it is at present unclear what proportion of circulating OPG is monomeric, dimeric or bound to RANK-L [10,24], it seems reasonable to use an assay that detects all forms of circulating OPG.”
BackgroundInfluentialRogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200
“Assays are being developed that use OPG ligand as a capture protein as an alternative to an antihuman OPG monoclonal antibody (23).”
MethodFarr, J. N., Charkoudian, N., Barnes, J. N., Monroe, D. G., McCready, L. K., Atkinson, E. J., Amin, S., Melton, L. J., Joyner, M. J., & Khosla, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2381 · Cited by 79
Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M. (2003) · Bone · doi:10.1016/j.bone.2003.08.001 · Cited by 7
“It is at present unclear what proportion of circulating OPG is monomeric, dimeric, or bound to RANK ligand (RANKL) [23].”
Background
Metadata
- Authors
- Chen, D., Sarikaya, N. A., Gunn, H., Martin, S. W., & Young, J. D.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 47
- Issue
- 4
- Pages
- 747-749
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2097140145
- Cited by
- 32
- References
- 7
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies. https://app.cochat.ai/papers/10.1093/clinchem/47.4.747
- The paper
- Chen, D., Sarikaya, N. A., Gunn, H., Martin, S. W., & Young, J. D. (2001). ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies. Clinical Chemistry. https://doi.org/10.1093/clinchem/47.4.747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.